A Multi-epitope Vaccine GILE Against Infection in Mice

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Feb 3

PMID 36733393

Authors

Pei Zhou

Zhen Zhou

Meiduo Huayu

Lei Wang

Lin Feng

Yang Xiao

Yao Dai

Mingyuan Xin

Feng Tang

Runle Li

Affiliations

Soon will be listed here.

Abstract

Introduction: The objective of this study is to construct a multi-epitope vaccine GILE containing B-cell and T-cell epitopes against () infection based on the dominant epitopes of EMY162, LAP, and GLUT1.

Methods: The structure and hydrophobicity of GILE were predicted by SWISSMODEL, pyMOL, SOPMA and VMD, and its sequence was optimized by Optimum™ Codon. The GILE gene was inserted into pCzn1 and transformed into Arctic express competent cells. IPTG was added to induce the expression of recombinant proteins. High-purity GILE recombinant protein was obtained by Ni-NTA Resin. BALB/c mice were immunized with GILE mixed with Freund's adjuvant, and the antibody levels and dynamic changes in the serum were detected by ELISA. Lymphocyte proliferation was detected by MTS. The levels of IFN-g and IL-4 were detected by ELISpot and flow cytometry (FCM). T cells were detected by FCM. The growth of hepatic cysts was evaluated by Ultrasound and their weights were measured to evaluate the immune protective effect of GILE.

Results: The SWISS-MODEL analysis showed that the optimal model was EMY162 -LAP-LAP-LAP-LAP-EMY162. The SOPMA results showed that there were Alpha helix (14.88%), Extended strand (26.25%), Beta turn (3.73%) and Random coil (45.82%) in the secondary structure of GILE. The restriction enzyme digestion and sequencing results suggested that the plasmid pCzn1-GILE was successfully constructed. The SDSPAGE results indicated that the recombinant protein was 44.68 KD. The ELISA results indicated that mice immunized with GILE showed higher levels of serum antibodies compared to the PBS group. The FCM and ELISpot results indicated that mice immunized with GILE secreted more IFN-g and IL-4. Immunization with GILE also led to a significant decrease in the maximum diameter and weight of cysts and stimulated the production of CD4 and CD8 T Cell.

Discussion: A multi-epitope vaccine GILE with good immunogenicity and antigenicity has been successfully constructed in this study, which may provide important theoretical and experimental bases for the prevention and treatment of infection.

Citing Articles

Efficacy and safety of pseudolaric acid B against and in a murine infection model.

Dawa Z, Zhai T, Liu C, Fan H Front Med (Lausanne). 2025; 12:1503472.

PMID: 39944494 PMC: 11813755. DOI: 10.3389/fmed.2025.1503472.

Designing of a multiepitope-based vaccine against echinococcosis utilizing the potent Ag5 antigen: Immunoinformatics and simulation approaches.

Parvin R, Masum M, Heema H, Akter A, Hossain M, Siddiki A PLoS One. 2025; 20(2):e0310510.

PMID: 39937717 PMC: 11819600. DOI: 10.1371/journal.pone.0310510.

Novel dual-pathogen multi-epitope mRNA vaccine development for Brucella melitensis and Mycobacterium tuberculosis in silico approach.

Zhu Y, Shi J, Wang Q, Zhu Y, Li M, Tian T PLoS One. 2024; 19(10):e0309560.

PMID: 39466745 PMC: 11515988. DOI: 10.1371/journal.pone.0309560.

Design of a novel EmTSP-3 and EmTIP based multi-epitope vaccine against infection.

Fan Y, He Y, Li Y, Yin Z, Shi J, Tian T Front Immunol. 2024; 15:1425603.

PMID: 39351224 PMC: 11439721. DOI: 10.3389/fimmu.2024.1425603.

Current status and future prospects of vaccine candidates: A systematic review.

Hataminejad M, Anvari D, Khaleghi N, Nayeri T, Shirazinia R, Shariatzadeh S Vet Anim Sci. 2024; 24:100345.

PMID: 38516388 PMC: 10950815. DOI: 10.1016/j.vas.2024.100345.

References

Gottstein B, Haag K, Walker M, Matsumoto J, Mejri N, Hemphill A . Molecular survival strategies of Echinococcus multilocularis in the murine host. Parasitol Int. 2005; 55 Suppl:S45-9. DOI: 10.1016/j.parint.2005.11.006. View

Liu C, Fan H, Guan L, Ge R, Ma L . In vivo and in vitro efficacy of crocin against Echinococcus multilocularis. Parasit Vectors. 2021; 14(1):364. PMC: 8278753. DOI: 10.1186/s13071-021-04866-4. View

Brunetti E, Kern P, Vuitton D . Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2009; 114(1):1-16. DOI: 10.1016/j.actatropica.2009.11.001. View

Zhang W, Ross A, McManus D . Mechanisms of immunity in hydatid disease: implications for vaccine development. J Immunol. 2008; 181(10):6679-85. DOI: 10.4049/jimmunol.181.10.6679. View

Wang H, Zhang F, Ma X, Ma H, Zhu Y, Liu X . Prokaryotic expression and identification of B- and T-cell combined epitopes of Em95 antigen of Echinococcus multilocularis. Int J Clin Exp Pathol. 2014; 7(8):5117-22. PMC: 4152075. View

Xu K, Ahan A . A new dawn in the late stage of alveolar echinococcosis "parasite cancer". Med Hypotheses. 2020; 142:109735. DOI: 10.1016/j.mehy.2020.109735. View

Bresson-Hadni S, Spahr L, Chappuis F . Hepatic Alveolar Echinococcosis. Semin Liver Dis. 2021; 41(3):393-408. DOI: 10.1055/s-0041-1730925. View

Wang Y, Han X, Wang H . [Cloning and expression of echinococcus granulosus Eg18 and preliminary evaluation of immunological assay with recombinant antigen]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2011; 23(2):192-6. View

Wei W, Wang L, Zhou P, Jiang B, Liu H, Feng L . Bioinformatic prediction and identification of immunogenic epitopes of the antigenic 14-3-3 protein of Echinococcus multilocularis. Acta Trop. 2021; 220:105955. DOI: 10.1016/j.actatropica.2021.105955. View

10.

Zhang S, Hue S, Sene D, Penfornis A, Bresson-Hadni S, Kantelip B . Expression of major histocompatibility complex class I chain-related molecule A, NKG2D, and transforming growth factor-beta in the liver of humans with alveolar echinococcosis: new actors in the tolerance to parasites?. J Infect Dis. 2008; 197(9):1341-9. DOI: 10.1086/586709. View

11.

Deplazes P, Rinaldi L, Alvarez Rojas C, Torgerson P, Harandi M, Romig T . Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol. 2017; 95:315-493. DOI: 10.1016/bs.apar.2016.11.001. View

12.

Park A, Scott P . Il-12: keeping cell-mediated immunity alive. Scand J Immunol. 2001; 53(6):529-32. DOI: 10.1046/j.1365-3083.2001.00917.x. View

13.

Akbari M, Kimura K, Bayarsaikhan G, Kimura D, Miyakoda M, Juriasingani S . Nonspecific CD8 T Cells and Dendritic Cells/Macrophages Participate in Formation of CD8 T Cell-Mediated Clusters against Malaria Liver-Stage Infection. Infect Immun. 2018; 86(4). PMC: 5865025. DOI: 10.1128/IAI.00717-17. View

14.

Dang Z, Yagi K, Oku Y, Kouguchi H, Kajino K, Watanabe J . Evaluation of Echinococcus multilocularis tetraspanins as vaccine candidates against primary alveolar echinococcosis. Vaccine. 2009; 27(52):7339-45. DOI: 10.1016/j.vaccine.2009.09.045. View

15.

Gupta S, Garg N . Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis. 2010; 4(8):e797. PMC: 2919396. DOI: 10.1371/journal.pntd.0000797. View

16.

Boubaker G, Hemphill A, Huber C, Spiliotis M, Babba H, Gottstein B . Prevention and Immunotherapy of Secondary Murine Alveolar Echinococcosis Employing Recombinant EmP29 Antigen. PLoS Negl Trop Dis. 2015; 9(6):e0003795. PMC: 4460070. DOI: 10.1371/journal.pntd.0003795. View

17.

Wang H, Zhang C, Fang B, Hou J, Li W, Li Z . Dual Role of Hepatic Macrophages in the Establishment of the Metacestode in Mice. Front Immunol. 2021; 11:600635. PMC: 7820908. DOI: 10.3389/fimmu.2020.600635. View

18.

Kashiide T, Kikuta S, Yamaguchi M, Irie T, Kouguchi H, Yagi K . Molecular and functional characterization of glucose transporter genes of the fox tapeworm Echinococcus multilocularis. Mol Biochem Parasitol. 2018; 225:7-14. DOI: 10.1016/j.molbiopara.2018.08.004. View

19.

Mejri N, Muller N, Hemphill A, Gottstein B . Intraperitoneal Echinococcus multilocularis infection in mice modulates peritoneal CD4+ and CD8+ regulatory T cell development. Parasitol Int. 2010; 60(1):45-53. DOI: 10.1016/j.parint.2010.10.002. View

20.

Vuitton D, Gottstein B . Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay. J Biomed Biotechnol. 2010; 2010:923193. PMC: 2842905. DOI: 10.1155/2010/923193. View